[
  {
    "ts": null,
    "headline": "3 Dividend-Paying Drug Stocks to Buy at a Discount",
    "summary": "Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?",
    "url": "https://finnhub.io/api/news?id=8279545e1f4f5bdecd28252969f8e5e1a2b2d7c97b2bd40da73ad2885e5d5e61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761588000,
      "headline": "3 Dividend-Paying Drug Stocks to Buy at a Discount",
      "id": 137231008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?",
      "url": "https://finnhub.io/api/news?id=8279545e1f4f5bdecd28252969f8e5e1a2b2d7c97b2bd40da73ad2885e5d5e61"
    }
  },
  {
    "ts": null,
    "headline": "Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences",
    "summary": "Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company",
    "url": "https://finnhub.io/api/news?id=4a36153c33d86e102e2eadb2004498797b0af257b80aa783b4a55d6d6034d794",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761583500,
      "headline": "Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences",
      "id": 137231074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company",
      "url": "https://finnhub.io/api/news?id=4a36153c33d86e102e2eadb2004498797b0af257b80aa783b4a55d6d6034d794"
    }
  },
  {
    "ts": null,
    "headline": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
    "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=ca78798d5c35458977cd4299c0e5768b36fad842a89b3c5c6895bce2a89bf150",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761582082,
      "headline": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
      "id": 137230311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=ca78798d5c35458977cd4299c0e5768b36fad842a89b3c5c6895bce2a89bf150"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Pfizer Stock Before Nov. 4?",
    "summary": "The pharma giant is slated to report its latest quarterly numbers next week.",
    "url": "https://finnhub.io/api/news?id=8701d0e726b3e15da85ee39656a006c93117c691e12f4d720ad5509f7df1df15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761581700,
      "headline": "Should You Buy Pfizer Stock Before Nov. 4?",
      "id": 137231076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant is slated to report its latest quarterly numbers next week.",
      "url": "https://finnhub.io/api/news?id=8701d0e726b3e15da85ee39656a006c93117c691e12f4d720ad5509f7df1df15"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?",
    "summary": "Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.",
    "url": "https://finnhub.io/api/news?id=ea1afeadec764e7dde5d7f19d3e2a2189016a9e6a88b3e31507606530dc6ae61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571020,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?",
      "id": 137228785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.",
      "url": "https://finnhub.io/api/news?id=ea1afeadec764e7dde5d7f19d3e2a2189016a9e6a88b3e31507606530dc6ae61"
    }
  },
  {
    "ts": null,
    "headline": "2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000",
    "summary": "These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again.",
    "url": "https://finnhub.io/api/news?id=5e52df9953cf0aa32943ac8261d50a132c0374475f1dcc68b53bedb38ab5168a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761566400,
      "headline": "2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000",
      "id": 137228787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again.",
      "url": "https://finnhub.io/api/news?id=5e52df9953cf0aa32943ac8261d50a132c0374475f1dcc68b53bedb38ab5168a"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
    "summary": "Vertex appears to be by far the better buy right now.",
    "url": "https://finnhub.io/api/news?id=8852232a228289b06516240d36fffe2ab383726f295a627ec84fbfee93ca8dcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761558180,
      "headline": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
      "id": 137228788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vertex appears to be by far the better buy right now.",
      "url": "https://finnhub.io/api/news?id=8852232a228289b06516240d36fffe2ab383726f295a627ec84fbfee93ca8dcd"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2025",
    "summary": "If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.",
    "url": "https://finnhub.io/api/news?id=3242a30418a90de8e987e5ec748974c8698cd8960f21d5a9033997b646c5e1ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761553800,
      "headline": "3 Healthcare Stocks Paying the Highest Dividends of 2025",
      "id": 137228566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.",
      "url": "https://finnhub.io/api/news?id=3242a30418a90de8e987e5ec748974c8698cd8960f21d5a9033997b646c5e1ef"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s oncology prospects could portend a post-Keytruda future",
    "summary": "Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?",
    "url": "https://finnhub.io/api/news?id=014d761b91b18dec4df3fb487175576a60384ea504bbe1248c31fce9ae6c27c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761552000,
      "headline": "Merck’s oncology prospects could portend a post-Keytruda future",
      "id": 137228666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?",
      "url": "https://finnhub.io/api/news?id=014d761b91b18dec4df3fb487175576a60384ea504bbe1248c31fce9ae6c27c7"
    }
  }
]